On Tuesday, Neurocrine Biosciences, Inc (NASDAQ: NBIX) was -3.43% drop from the session before settling in for the closing price of $143.56. A 52-week range for NBIX has been $84.23 – $157.67.
A company in the Healthcare sector has jumped its sales by 53.47% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 55.34%. With a float of $97.00 million, this company’s outstanding shares have now reached $99.70 million.
Neurocrine Biosciences, Inc (NBIX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Neurocrine Biosciences, Inc stocks. The insider ownership of Neurocrine Biosciences, Inc is 2.71%, while institutional ownership is 98.28%. The most recent insider transaction that took place on Nov 05 ’25, was worth 2,732,690. In this transaction Director of this company sold 18,000 shares at a rate of $151.82, taking the stock ownership to the 40,360 shares. Before that another transaction happened on Nov 04 ’25, when Company’s Officer proposed sale 300 for $141.97, making the entire transaction worth $42,591.
Neurocrine Biosciences, Inc (NBIX) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted 1.69 earnings per share (EPS) during the time that was less than consensus figure (set at 1.93) by -0.24. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 55.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 35.95% during the next five years compared to 53.47% growth over the previous five years of trading.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Trading Performance Indicators
You can see what Neurocrine Biosciences, Inc (NBIX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.15. Likewise, its price to free cash flow for the trailing twelve months is 23.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 4.19, a number that is poised to hit 1.86 in the next quarter and is forecasted to reach 7.04 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc (NBIX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.97 million. That was inferior than the volume of 1.17 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 10.83%.
During the past 100 days, Neurocrine Biosciences, Inc’s (NBIX) raw stochastic average was set at 44.00%, which indicates a significant increase from 10.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 5.03 in the past 14 days, which was higher than the 3.49 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $142.53, while its 200-day Moving Average is $126.65. However, in the short run, Neurocrine Biosciences, Inc’s stock first resistance to watch stands at $143.00. Second resistance stands at $147.36. The third major resistance level sits at $149.65. If the price goes on to break the first support level at $136.35, it is likely to go to the next support level at $134.06. The third support level lies at $129.70 if the price breaches the second support level.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Key Stats
There are 99,706K outstanding shares of the company, which has a market capitalization of 13.82 billion. As of now, sales total 2,355 M while income totals 341,300 K. Its latest quarter income was 794,900 K while its last quarter net income were 209,500 K.
